Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol ARRY
Array BioPharma
ARRY
81
$12.42arrow_drop_down4.31%-$0.56

Performance History

Chart placeholder
Key Stats
Open$12.93
Prev. Close$12.98
EPS0.38
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$2.06B
PE Ratio32.68
LOWHIGH
Day Range12.38
13.01
52 Week Range10.59
26.64
Ratios
P/B Ratio7.57
Revenue$1.57B
Operating M. %2.40%
Earnings$137.24M
Earnings Growth %2,996.57%
EBITDA Margin %13.41%
ROE %19.68%
EPS0.38

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$442.57
24H (%)arrow_drop_up0.22%
24H ($)$0.99
MARKET CAP$3.18T
PRICE$212.49
24H (%)arrow_drop_down0.81%
24H ($)-$1.75
MARKET CAP$2.91T
PRICE$131.88
24H (%)arrow_drop_up1.75%
24H ($)$2.27
MARKET CAP$2.82T
PRICE$1,735.04
24H (%)arrow_drop_up3.33%
24H ($)$56.05
MARKET CAP$644.46B

About Array BioPharma (ARRY)

Array Technologies, Inc. manufactures and sells ground-mounting tracking systems used in solar energy projects in the United States, Spain, Brazil, Australia, and internationally. The company operates in two segments, Array Legacy Operations and STI Operations. Its products include DuraTrack HZ v3, a single axis tracker; Array STI H250 to deliver a lower levelized cost of energy with tracker system; Array OmniTrack; and SmarTrack, a software product that uses site-specific historical weather and energy production data in combination with machine learning algorithms to identify the optimal position for a solar array in real time to enhance its energy production. The company was founded in 1989 and is headquartered in Albuquerque, New Mexico.

Sector
Technology
Industry
Solar
CEO
Mr. Kevin G. Hostetler
Headquarters
Albuquerque
Employees
1050
Exchange
NASDAQ
add Array BioPharma  to watchlist

Keep an eye on Array BioPharma

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Array BioPharma 's (ARRY) price per share?

The current price per share for Array BioPharma (ARRY) is $12.42. The stock has seen a price change of -$0.56 recently, indicating a -4.31% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Array BioPharma (ARRY)?

For Array BioPharma (ARRY), the 52-week high is $26.64, which is 114.49% from the current price. The 52-week low is $10.6, the current price is 17.23% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Array BioPharma (ARRY) a growth stock?

Array BioPharma (ARRY) has shown an average price growth of 0.41% over the past three years. It has received a score of 84 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Array BioPharma as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Array BioPharma (ARRY) stock price performance year to date (YTD)?

As of the latest data, Array BioPharma (ARRY) has a year-to-date price change of -26.77%. Over the past month, the stock has experienced a price change of 1.47%. Over the last three months, the change has been 5.88%. Over the past six months, the figure is -34.29%. Looking at a longer horizon, the five-year price change stands at -73.26%.

help
Is Array BioPharma (ARRY) a profitable company?

Array BioPharma (ARRY) has a net income of $137.24M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 23.89% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 2.4% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.58B, although specific revenue growth data is currently not available. The gross profit is $376.62M. Operating income is noted at $217.09M. Furthermore, the EBITDA is $238.94M.

help
What is the market capitalization of Array BioPharma (ARRY)?

Array BioPharma (ARRY) has a market capitalization of $2.07B. The average daily trading volume is 4.41M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level